See more : Sera Prognostics, Inc. (SERA) Income Statement Analysis – Financial Results
Complete financial analysis of Shanghai Bio-heart Biological Technology Co., Ltd. (2185.HK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Shanghai Bio-heart Biological Technology Co., Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- Tera Autotech Corporation (6234.TWO) Income Statement Analysis – Financial Results
- Brookfield Asset Management Inc (BKFAF) Income Statement Analysis – Financial Results
- Cyient DLM Limited (CYIENTDLM.BO) Income Statement Analysis – Financial Results
- Trifecta Gold Ltd. (TRRFF) Income Statement Analysis – Financial Results
- GD Culture Group Limited (GDC) Income Statement Analysis – Financial Results
Shanghai Bio-heart Biological Technology Co., Ltd. (2185.HK)
About Shanghai Bio-heart Biological Technology Co., Ltd.
Shanghai Bio-heart Biological Technology Co., Ltd. operates as an interventional cardiovascular device company in the People's Republic of China. The company focuses on the provision of bioresorbable scaffolds (BRS) and renal denervation (RDN) therapies for the treatment of coronary artery diseases and uncontrolled and resistant hypertension. It is developing Bioheart, a BRS system used in percutaneous coronary intervention procedures for the treatment of coronary artery disease; Iberis 2nd, a multi-electrode RDN product candidate; and drug coated balloon, a sirolimus drug-eluting balloon catheter designed for instent restenosis. The company has collaboration agreements with Terumo (China) Investment Co., Ltd. to conduct clinical trials for Iberis 2nd. Shanghai Bio-heart Biological Technology Co., Ltd. was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 23.60M | 24.25M | 15.95M | 9.71M | 7.69M |
| Gross Profit | -23.60M | -24.25M | -15.95M | -9.71M | -7.69M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 111.74M | 168.73M | 248.29M | 267.12M | 14.35M |
| General & Administrative | 16.09M | 13.27M | 29.74M | 81.56M | 0.00 |
| Selling & Marketing | 33.25M | 87.03M | 199.74M | 9.66M | 0.00 |
| SG&A | 49.34M | 100.29M | 229.48M | 91.22M | 3.21M |
| Other Expenses | -2.77M | -50.00K | 278.00K | 193.00K | 0.00 |
| Operating Expenses | 158.31M | 269.02M | 477.77M | 358.34M | 17.55M |
| Cost & Expenses | 163.68M | 293.28M | 493.72M | 368.05M | 25.24M |
| Interest Income | 4.00M | 4.01M | 972.00K | 190.00K | 0.00 |
| Interest Expense | 578.00K | 959.00K | 685.00K | 56.00K | 0.00 |
| Depreciation & Amortization | 23.60M | 24.25M | 15.95M | 9.71M | 7.69M |
| EBITDA | -158.31M | -209.05M | -477.77M | -358.34M | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -181.91M | -293.28M | -493.72M | -368.05M | -25.24M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -6.91M | 26.47M | -208.50K | -14.34M | 1.55M |
| Income Before Tax | -188.82M | -266.81M | -493.93M | -382.39M | -23.69M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 5.54M | -29.31M | -58.30M | -16.60M | 2.64 |
| Net Income | -194.36M | -237.50M | -435.62M | -365.79M | -23.69M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.80 | -0.98 | -1.79 | -1.50 | -0.10 |
| EPS Diluted | -0.80 | -0.98 | -1.79 | -1.50 | -0.10 |
| Weighted Avg Shares Out | 243.42M | 243.42M | 243.94M | 243.94M | 243.94M |
| Weighted Avg Shares Out (Dil) | 243.42M | 243.42M | 243.94M | 243.94M | 243.94M |
Source: https://incomestatements.info
Category: Stock Reports